Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients

Study Overview
=================
Brief Summary
-----------------
Pneumocystis jirovecii pneumonia (PjP) is a rare infectiouse disease with a high level of mortality. PjP is a classical opportunistic infection which concern HIV infected and immunocompromised patients. During the past decade, several therapeutic's progresses have been done in oncology, immunology and hematology. As a consequence, patients benefited of greater treatment efficacy but are exposed to a higher risk of opportunistic infections as PjP. The investigators hypothesis is that PjP incidence increase and its form is depending of underlying immune conditions. The investigators aim to describe its incidence, the PjP forms depending on comorbidities and to identifiy pronostics factors.

Official Title
-----------------
Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients : a Prognostic Observational Retrospective Monocentre Study

Conditions
-----------------
Pneumocystis Jirovecii Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Underlying immune condition at risk of Pneumocystis jirovecii pneumonia excluding HIV infection Clinical, biological and radiological presentation which evoke Pneumocystis jirovecii pneumonia Microbiological confirmation by respiratory specimen analyses ( specific coloration and/or IFI and/or PRC) Exclusion Criteria: No microbiological confirmation by respiratory specimen analyses Proved HIV infection Patient denied to particpate
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Pneumocystis jirovecii pneumonia in HIV-free patients | Number of cases / number of patients treated for a predisposing disease (heamotological or imunological disease, or cancer...) | Between the first january 2004 and the 31th december 2021 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe the age of giv free patients with Pneumocystis jirovecci pneumonia | age in years | Between the first january 2004 and the 31th december 2021 | 
| To describe the body mass index of HIV free patients with Pneumocystis jirovecci pneumonia | BMI in kg/m2 (quanti | Between the first january 2004 and the 31th december 2021 | 
| To describe the Charlson comorbidity index of HIV free patients with Pneumocystis jirovecci pneumonia | Charlson comorbidity index as a quantitative variable | Between the first january 2004 and the 31th december 2021 | 
| To describe the comoribidites of HIV-free patients with Pneumocystis jirovecci pneumonia | Comorbidities as categorial variables | Between the first january 2004 and the 31th december 2021 | 
| To describe the previous medications used by HIV free patients with Pneumocystis jirovecci pneumonia | Medications as categorial variables | Between the first january 2004 and the 31th december 2021 | 
| To describe clinical features of Pneumocystis jirovecci pneumonia in HIV-free patients | Type of first symptoms as categorial variables | Between the first january 2004 and the 31th december 2021 | 
| To describe the date of the first symptoms of Pneumocystis jirovecci pneumonia in HIV-free patients | Date of first symptoms as quantitative variable | Between the first january 2004 and the 31th december 2021 | 
| To describe the pO2 level of HIV free patients with Pneumocystis jirovecci pneumonia | pO2 (in mmHg) | Between the first january 2004 and the 31th december 2021 | 
| To describe the PCR level of HIV free patients with Pneumocystis jirovecci pneumonia | PCR (mg/L) | Between the first january 2004 and the 31th december 2021 | 
| To describe the WBC level of HIV free patients with Pneumocystis jirovecci pneumonia | WBC (G/L) | Between the first january 2004 and the 31th december 2021 | 
| To describe the creatinine level of HIV free patients with Pneumocystis jirovecci pneumonia | Creatinine (µmol/L) | Between the first january 2004 and the 31th december 2021 | 
| To describe the LDH level of HIV free patients with Pneumocystis jirovecci pneumonia | LDH (MUI/L) | Between the first january 2004 and the 31th december 2021 | 
| To describe the albumin level of HIV free patients with Pneumocystis jirovecci pneumonia | albumin (g/L) | Between the first january 2004 and the 31th december 2021 | 
| To describe the immunoglobulin level of HIV free patients with Pneumocystis jirovecci pneumonia | immunoglobulin (g/L) | Between the first january 2004 and the 31th december 2021 | 
| To describe the lymphocytes level of HIV free patients with Pneumocystis jirovecci pneumonia | lymphocytes (G/L) | Between the first january 2004 and the 31th december 2021 | 
| To describe the PCR pneumocystis level of HIV free patients with Pneumocystis jirovecci pneumonia | PCR pneumocystis in ct | Between the first january 2004 and the 31th december 2021 | 
| To describe the immunofluorescence value of HIV free patients with Pneumocystis jirovecci pneumonia | Immunofluorescence as a categorial variable | Between the first january 2004 and the 31th december 2021 | 
| To describe the specific coloration value of HIV free patients with Pneumocystis jirovecci pneumonia | Specific coloration as a categorial variable | Between the first january 2004 and the 31th december 2021 | 
| To describe the use of nasal canula in HIV free patient with a Pneumocystis jirovecci pneumonia | Nasal canula as a categorial variable | Between the first january 2004 and the 31th december 2021 | 
| To describe the use of high flow oxygenation in HIV free patient with a Pneumocystis jirovecci pneumonia | High flow oxygenation as a categorial variable | Between the first january 2004 and the 31th december 2021 | 
| To describe the use of mechanical ventilation in HIV free patient with a Pneumocystis jirovecci pneumonia | Mechanical ventilation as a categorial variable | Between the first january 2004 and the 31th december 2021 | 
| To describe the duration of hospitalisation of HIV free patients with Pneumocystis carinii pneumonia | Duration in days | Between the first january 2004 and the 31th december 2021 | 
| To describe the use of cotrimoxazole for HIV free patients with Pneumocystis carinii pneumonia | cotrimoxazole as a categorial variable | Between the first january 2004 and the 31th december 2021 | 
| To describe the use of atovaquone for HIV free patients with Pneumocystis carinii pneumonia | atovaquone as a categorial variable | Between the first january 2004 and the 31th december 2021 | 
| To describe the use of pentamidine for HIV free patients with Pneumocystis carinii pneumonia | pentamidine as a categorial variable | Between the first january 2004 and the 31th december 2021 | 
| To describe the use of steroïd for HIV free patients with Pneumocystis carinii pneumonia | steroïd as a categorial variable | Between the first january 2004 and the 31th december 2021 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pneumocystis jirovecii pneumonia, HIV-free patients